- Home
- / Open Orphan
Open Orphan
Stock Price
£0.1
2022-12-23
Market Capitalization
£67.1 M
2022-12-23
Revenue
€46.8 M
FY, 2025
Open Orphan Summary
Company Summary
- Overview
- Open Orphan is a CRO pharmaceutical services company with a focus on orphan drugs. It is engaged in the testing of vaccines and antivirals through the use of human challenge clinical trials.
- Type
- Public
- Status
- Active
- Founded
- 2017
- Website
- https://www.openorphan.com
- Cybersecurity rating
Table of Contents
Key People
Leo Toole, Chief Financial Officer
Andrew Catchpole, Chief Scientific Officer
Brendan Buckley, Non-Executive Director
Open Orphan Financials
Summary Financials
- Revenue (FY, 2025)
- €46.8M
- Gross profit (FY, 2025)
- €47.4M
- Net income (FY, 2025)
- (€6.0M)
- Cash (FY, 2025)
- €14.3M
- EBIT (FY, 2025)
- (€4.6M)
- Enterprise value
- $67.6M